Spero Therapeutics (SPRO) Cash & Current Investments (2016 - 2026)

Spero Therapeutics has reported Cash & Current Investments for 11 years, with the latest figure at $56.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 14.81% year-over-year to $56.1 million; the trailing twelve-month figure through Mar 2026 stood at $56.1 million (up 14.81% YoY), and the FY2025 full-year result was $40.3 million, down 23.87% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $56.1 million, up from $40.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $122.0 million in Q1 2022, with the low at $31.2 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $68.9 million across 5 years, with a median of $63.5 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 59.13% — and 2023, when it jumped 85.99%.
• Spero Therapeutics' Cash & Current Investments stood at $109.1 million in 2022, then slumped by 30.04% to $76.3 million in 2023, then slumped by 30.71% to $52.9 million in 2024, then declined by 23.87% to $40.3 million in 2025, then surged by 39.4% to $56.1 million in 2026.
• The last three Cash & Current Investments figures came in at $56.1 million (Q1 2026), $40.3 million (Q4 2025), and $48.6 million (Q3 2025), per Business Quant data.